Business context and reporting period
Issuer mismatch: The supplied filing is Anzu Special Acquisition Corp I’s Form 10-Q for the quarter ended September 30, 2021, not a filing by Envoy Medical, Inc. Anzu is a blank-check company seeking a business combination, with an intended focus on businesses using transformative technologies for industrial applications. It had not begun operations or generated operating revenue and had not announced a definitive transaction.
Financial results and position
- Revenue and earnings: No operating revenue. Net income was $5.57 million for the third quarter and $4.47 million for the nine months ended September 30, 2021. Results were driven by noncash warrant-liability fair-value gains of $8.55 million and $9.46 million, respectively, rather than operating performance. Formation and operating costs were $2.99 million and $4.24 million.
- Cash flow: Nine-month operating cash use was $2.36 million. The company placed $425.0 million in its trust account; cash at period-end was $1.03 million, compared with $25,000 at December 31, 2020.
- Liquidity: Working capital was negative $851,101. The trust account held $425.03 million, primarily for a future business combination or public-share redemptions; those funds are generally unavailable for ordinary operating expenses.
- Debt and obligations: No long-term debt or working-capital loans were outstanding. Current liabilities were $2.77 million, including $1.97 million of accrued expenses. A $14.875 million deferred underwriting fee is payable only if a business combination is completed. Warrant liabilities totaled $17.07 million.
- Equity and margins: All 42.5 million public Class A shares, valued at $425.0 million, were classified as temporary equity subject to possible redemption. Permanent stockholders’ equity was negative $32.76 million. Operating margins are not meaningful because the company had no revenue.
Changes versus prior comparable period
The filing presents results for the three and nine months ended September 30, 2021 but does not provide prior-year operating results; Anzu was incorporated in December 2020 and completed its IPO in March 2021. Compared with December 31, 2020, the company had raised $425.0 million in its IPO and placed the proceeds in trust, while warrant liabilities and substantial redeemable public shares were newly recorded.
The company revised previously issued interim financial statements to classify all redeemable Class A shares as temporary equity. Management said the revision did not change total assets, liabilities, or operating results; it substantially reduced reported permanent equity.
Outlook, risks and unusual items
- Management continued to review acquisition opportunities but could not determine whether it would complete a transaction. No revenue is expected before a business combination.
- The company must complete a business combination by March 4, 2023, unless stockholders approve an extension, or it must wind up and redeem public shares. Warrants may expire worthless if no transaction is completed.
- Management warned that limited cash outside the trust could be insufficient for operating and transaction-search costs. The sponsor is not required to provide funding; management said these conditions raise substantial doubt about the company’s ability to continue as a going concern through one year from the financial-statement date if no combination is completed.
- COVID-19 could adversely affect the company’s financial position or target search, but the specific impact was not determinable. No material legal proceedings or material changes to previously disclosed risk factors were reported.
- Warrant fair-value gains materially shaped reported net income. Management reported disclosure controls were effective and that a previously identified material weakness had been remediated.
Investor verification priorities
- Confirm the issuer: this filing is for Anzu Special Acquisition Corp I, not Envoy Medical, Inc.
- Assess cash available outside the trust, ongoing expenses, and the stated going-concern uncertainty; trust assets are restricted and primarily support a transaction or redemptions.
- Distinguish reported net income from operating performance: the company had no revenue, and income largely reflected warrant remeasurement gains.
- Review the warrant terms, potential dilution, redemption provisions, and the $14.875 million deferred underwriting fee due if a business combination closes.
- Check reported inconsistencies: the monthly administrative-fee amount is stated as both $40,521 and $40,251 in different sections, and IPO transaction costs are also reported with differing totals.